Biotech

All Articles

Pfizer takes $230M attacked after axing fell short DMD gene therapy

.Pfizer's period 3 Duchenne muscular dystrophy (DMD) gene treatment breakdown has actually gone a $2...

AC Immune finds 'spots' possible in Alzheimer's medicine data

.After greater than two decades of service neurodegenerative diseases, Swiss biotech a/c Immune syst...

GSK goes down ph. 2 HPV injection over shortage of best-in-class potential

.GSK has actually ditched a stage 2 individual papillomavirus (HPV) vaccination from its own pipe af...

OS Therapies refiles $6M IPO to fund HER2 medication, preclinical ADCs

.Operating system Therapies will certainly detail on the NYSE American inventory substitution today ...

ALX's waning CD47 action rate delivers sell spiraling down

.ALX Oncology's stage 2 stomach cancer cells reaction rate has actually damaged. After seeing its CD...

Ionis axes eye illness coming from intendeds of Roche-partnered prospect after data dissatisfy

.Another of Ionis Pharmaceuticals' essential midphase readouts has fallen short of desires, promptin...

Biogen's chief executive officer pointed out no high-risk deals in 2023. He's ready to become daring

.While Biogen's pharma peers are actually seeking for late-stage possessions with little bit of thre...

Instil refills pipeline in $2B biobucks manage ImmunOnco

.Instil Bio has been actually a biotech looking for a pipe after it ditched its own lead properties ...

Biogen ignores Denali Alzheimer's collab

.Biogen has actually returned liberties to a very early Alzheimer's condition plan to Denali Therape...

Takeda taps new mind people oncology service-- Chutes &amp Ladders

.Accept to this week's Chutes &amp Ladders, our summary of considerable leadership hirings, shooting...